

Special Issue

Biochemical and Cellular Mechanisms Regulating ER-to-Golgi Vesicular Trafficking in Health and Disease

Message from the Guest Editors

Secretory proteins and membranes exit the ER into ER-derived carriers and are transported to the Golgi before being sorted and delivered to their final destinations. This task is fundamental for the maintenance and function of secretory pathway compartments as well as for extracellular environment roles. The Unfolded Protein Response pathways, which preside over the control of proteostasis within the secretory pathway, the assembly of the multiprotein complex COPII at the ER membranes, and the ER-phagy are principal actors in ER-to-Golgi trafficking control. In this Special Issue, we welcome scientific contributions that describe novel cellular mechanisms and their interconnections implicated in ER-to-Golgi trafficking control and that discuss how defects of the molecular machinery that control ER-export result in diverse human diseases. We also welcome scientific reports that show and/or discuss possible therapeutic approaches that may be used in the treatment of ER-to Golgi trafficking-based disorders.

Guest Editors

Dr. Paolo Remondelli
Dr. Ornella Molteni
Dr. Giuseppina Amodio

Deadline for manuscript submissions

closed (30 April 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/102805

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).